NCT04324164Recruiting
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Source: ClinicalTrials.gov · Last updated 27 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 25 Mar 2020
- Start date
- Mar 2020
- Primary completion date
- Dec 2025
- Lead sponsor
- Hunan Province Tumor Hospital
- Diseases
- Lung cancer
- NCT number
- NCT04324164
What you commit to
- Study type: Observational
- Planned participants: 800
- From Mar 2020 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with contraindication of chemotherapy
Other
- Pregnant or breast feeding women
Who the study is looking for
- 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Uncommon EGFR Mutant Advanced NSCLC
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongchang Zhang Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.